New! EarlyCDT




Innovative blood test to aid in the early detection of lung cancer

Lung cancer is the leading cause of cancer death among men and women in the United States. Each year more people die of lung cancer than colon, breast, and prostate cancer combined. It is estimated that 226,160 new cases of lung cancer will be diagnosed and 160,340 deaths will occur in 2012.

-American Cancer Society 2012 Statistics

EarlyCDT®-Lung measures autoantibodies (immuno-biomarkers) in blood that form early in carcinogenesis. When the body recognizes something as “non-self,” one of the ways it responds is for the immune system to produce large amounts of antibodies. The immune system does not normally produce antibodies against normal tissue antigens and therefore these immuno-biomarkers to cancer antigens provide high specificity for cancer.

Patient blood samples are analyzed at Oncimmune’s CLIA-certified laboratory. Nearly 2,000 physicians are using the test. Fifteen peer-reviewed publications support its performance and clinical utility.

  • Specificity (93%), 7 times fewer false positives and 7 times better positive predictive value (PPV) than computerized tomography CT
  •  Greater than 91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand)

For more information:

To Order the Test:


  • Chapman CJ, et al. EarlyCDT-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biology 2012;33:1319-26.
  • The National Lung Cancer Screening Trial Research Team. N Engl J Med 2006;365:395-409.
  • Swensen SJ, et al. Radiology 2005;235:259-65.
  • Swensen SJ, et al. Am J Respir Crit Care Med 2002;165:508-13.
  • Van Klaveren RJ, et al. N Engl J Med 2009;361:2221-9.
  • Chapman C, et al. Chest 2010;138:s775A.

Connect With Us!

© 2016 Pathology, Inc.